All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID-19 mild to moderate - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
FACCT Trial, 2021 0.69 [0.28; 1.68]
GS-US-540-5774, 10 days, 2020 0.77 [0.17; 3.50]
GS-US-540-5774, 5 days, 2020 0.52 [0.09; 2.86]
Krolewiecki, 2020 0.49 [0.01; 26.05]
Pandit, 2021 0.95 [0.02; 50.33]
PLACID, 2020 1.04 [0.66; 1.63]
RAPID (Sholzberg), 2021 0.22 [0.07; 0.67]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
0.74 [0.49 ; 1.12 ] COL-COVID (Pascual-Figal), 2021, FACCT Trial, 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Krolewiecki, 2020, Pandit, 2021, PLACID, 2020, RAPID (Sholzberg), 2021, Shashi Bhushan, 2021 9 7% 2,404 serious not evaluable death or transfer to ICUdetailed results PLACID, 2020 1.07 [0.73; 1.57]
RAPID (Sholzberg), 2021 0.70 [0.44; 1.12]
0.89 [0.59 ; 1.34 ] PLACID, 2020, RAPID (Sholzberg), 2021 2 46% 929 serious not evaluable deathsdetailed results ChiCTR2000030054-HCQ (Chen), 2020 0.66 [0.01; 35.52]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.64 [0.18; 2.24]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.09 [0.31; 3.84]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.43 [0.13; 1.44]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
Dabbous HM, 2020 0.51 [0.02; 15.41]
FACCT Trial, 2021 0.96 [0.44; 2.08]
Fu, 2020 1.00 [0.02; 51.66]
GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40]
GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84]
HC-nCoV (Shanghai), 2020 1.00 [0.02; 53.89]
Khamis, 2020 0.83 [0.23; 2.96]
Krolewiecki, 2020 0.49 [0.01; 26.05]
Murugesan, 2022 1.00 [0.02; 51.41]
NCT04523831 (Mahmud), 2020 0.16 [0.01; 3.25]
NCT04542694, 2020 1.00 [0.02; 50.90]
Pandit, 2021 0.95 [0.02; 50.33]
PLACID, 2020 1.04 [0.66; 1.63]
RAPID (Sholzberg), 2021 0.22 [0.07; 0.67]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
Udwadia, 2020 0.50 [0.02; 15.03]
0.79 [0.59 ; 1.06 ] ChiCTR2000030054-HCQ (Chen), 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COL-COVID (Pascual-Figal), 2021, Dabbous HM, 2020, FACCT Trial, 2021, Fu, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, HC-nCoV (Shanghai), 2020, Khamis, 2020, Krolewiecki, 2020, Murugesan, 2022, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Pandit, 2021, PLACID, 2020, RAPID (Sholzberg), 2021, Shashi Bhushan, 2021, Udwadia, 2020 21 0% 4,565 moderate low deaths (time to event analysis only)detailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.64 [0.18; 2.24]
GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40]
GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84]
0.64 [0.28 ; 1.48 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 3 0% 1,141 moderate not evaluable clinical deteriorationdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.99 [0.57; 1.72]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.21 [0.69; 2.12]
COL-COVID (Pascual-Figal), 2021 0.38 [0.09; 1.58]
ELACOI (lopinavir/ritonavir), 2020 3.69 [0.37; 36.57]
ELACOI (Standard of care), 2020 0.86 [0.06; 11.36]
Kamran, 2020 0.95 [0.32; 2.78]
Li T, 2020 0.48 [0.01; 27.44]
NCT04523831 (Mahmud), 2020 0.44 [0.23; 0.84]
PLACID, 2020 1.04 [0.54; 1.99]
RAPID (Sholzberg), 2021 0.69 [0.43; 1.10]
Zhaowei Chen, 2020 0.11 [0.01; 2.19]
0.81 [0.62 ; 1.07 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COL-COVID (Pascual-Figal), 2021, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Kamran, 2020, Li T, 2020, NCT04523831 (Mahmud), 2020, PLACID, 2020, RAPID (Sholzberg), 2021, Zhaowei Chen, 2020 11 13% 2,802 moderate low clinical improvementdetailed results AVIFAVIR, 2020 0.53 [0.13; 2.19]
Chachar, 2020 1.19 [0.38; 3.72]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.81 [0.54; 1.22]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43]
Ghandehari, 2020 1.31 [1.00; 1.71]
GS-US-540-5774, 10 days, 2020 1.16 [0.77; 1.74]
GS-US-540-5774, 5 days, 2020 1.65 [1.09; 2.49]
NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38]
NCT04542694, 2020 2.10 [1.04; 4.24]
Ruzhentsova T, 2020 1.63 [1.14; 2.34]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
Tang, 2020 1.01 [0.59; 1.74]
Udwadia, 2020 1.75 [1.10; 2.79]
1.28 [1.07 ; 1.54 ] AVIFAVIR, 2020, Chachar, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, Ghandehari, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Ruzhentsova T, 2020, Shashi Bhushan, 2021, Tang, 2020, Udwadia, 2020 13 38% 3,002 moderate low clinical improvement (14-day)detailed results AVIFAVIR, 2020 0.53 [0.13; 2.19]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.01 [0.58; 1.76]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.83 [0.47; 1.44]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43]
GS-US-540-5774, 10 days, 2020 1.58 [1.01; 2.47]
GS-US-540-5774, 5 days, 2020 1.56 [1.00; 2.44]
Pandit, 2021 8.77 [0.94; 81.67]
Ruzhentsova T, 2020 1.28 [1.05; 1.56]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
1.17 [0.93 ; 1.47 ] AVIFAVIR, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Pandit, 2021, Ruzhentsova T, 2020, Shashi Bhushan, 2021 9 35% 2,516 moderate not evaluable clinical improvement (21-day)detailed results Li T, 2020 2.09 [0.04; 119.96]
2.09 [0.04 ; 119.96 ] Li T, 2020 1 0% 18 NA not evaluable clinical improvement (28-day)detailed results GS-US-540-5774, 10 days, 2020 1.88 [1.03; 3.42]
GS-US-540-5774, 5 days, 2020 1.75 [0.97; 3.17]
Ruzhentsova T, 2020 1.11 [0.96; 1.29]
Udwadia, 2020 1.75 [1.10; 2.79]
1.47 [1.06 ; 2.04 ] GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Ruzhentsova T, 2020, Udwadia, 2020 4 59% 1,102 moderate not evaluable clinical improvement (7-day)detailed results Chachar, 2020 1.19 [0.38; 3.72]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.89 [0.59; 1.35]
GS-US-540-5774, 10 days, 2020 1.03 [0.69; 1.53]
GS-US-540-5774, 5 days, 2020 1.41 [0.94; 2.09]
NCT04523831 (Mahmud), 2020 1.93 [1.27; 2.93]
NCT04542694, 2020 2.10 [1.04; 4.24]
Ruzhentsova T, 2020 1.50 [1.02; 2.21]
Shashi Bhushan, 2021 1.91 [1.03; 3.53]
1.39 [1.12 ; 1.74 ] Chachar, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Ruzhentsova T, 2020, Shashi Bhushan, 2021 8 39% 2,118 moderate not evaluable clinical improvement (time to event analysis only)detailed results FACCT Trial, 2021 0.85 [0.62; 1.16]
GS-US-540-5774, 10 days, 2020 1.16 [0.94; 1.44]
GS-US-540-5774, 5 days, 2020 1.15 [0.93; 1.42]
NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38]
Ruzhentsova T, 2020 1.63 [1.14; 2.34]
Tang, 2020 1.01 [0.59; 1.74]
Udwadia, 2020 1.75 [1.10; 2.79]
1.24 [1.02 ; 1.50 ] FACCT Trial, 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NCT04523831 (Mahmud), 2020, Ruzhentsova T, 2020, Tang, 2020, Udwadia, 2020 7 54% 1,887 moderate not evaluable death or ventilationdetailed results RAPID (Sholzberg), 2021 0.59 [0.34; 1.02]
0.59 [0.34 ; 1.02 ] RAPID (Sholzberg), 2021 1 0% 465 NA not evaluable hospital dischargedetailed results FACCT Trial, 2021 0.88 [0.64; 1.21]
Li T, 2020 10.00 [1.03; 97.50]
Udwadia, 2020 1.41 [0.97; 2.03]
1.26 [0.70 ; 2.25 ] FACCT Trial, 2021, Li T, 2020, Udwadia, 2020 3 72% 422 moderate not evaluable mechanical ventilationdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.77 [0.81; 3.87]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.54 [0.70; 3.37]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
GS-US-540-5774, 10 days, 2020 0.26 [0.03; 2.30]
GS-US-540-5774, 5 days, 2020 0.13 [0.01; 2.45]
Li T, 2020 0.40 [0.04; 3.90]
PLACID, 2020 0.99 [0.54; 1.81]
RAPID (Sholzberg), 2021 0.70 [0.32; 1.54]
Udwadia, 2020 0.06 [0.01; 0.83]
0.83 [0.49 ; 1.40 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COL-COVID (Pascual-Figal), 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Li T, 2020, PLACID, 2020, RAPID (Sholzberg), 2021, Udwadia, 2020 9 39% 2,511 moderate serious mechanical ventilation (time to event analysis only)detailed results Udwadia, 2020 0.06 [0.01; 0.83]
0.06 [0.01 ; 0.83 ] Udwadia, 2020 1 0% 14 NA not evaluable radiologic improvement (14-day)detailed results ELACOI (lopinavir/ritonavir), 2020 0.48 [0.02; 11.28]
ELACOI (Standard of care), 2020 0.18 [0.01; 3.99]
Rashad (CLARI vs SoC), 2021 2.87 [1.56; 5.28]
Rashad A (AZI vs SoC), 2021 1.64 [0.94; 2.88]
1.82 [0.95 ; 3.51 ] ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Rashad (CLARI vs SoC), 2021, Rashad A (AZI vs SoC), 2021 4 39% 450 moderate not evaluable radiologic improvement (7-day)detailed results ELACOI (lopinavir/ritonavir), 2020 0.10 [0.00; 2.09]
ELACOI (Standard of care), 2020 0.08 [0.00; 1.71]
Zhaowei Chen, 2020 3.43 [1.10; 10.70]
0.40 [0.02 ; 6.97 ] ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Zhaowei Chen, 2020 3 77% 108 moderate not evaluable viral clearance detailed results AVIFAVIR, 2020 3.89 [1.23; 12.29]
Dabbous HM, 2020 1.33 [0.60; 2.93]
ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76]
ELACOI (Standard of care), 2020 2.80 [0.31; 25.53]
HC-nCoV (Shanghai), 2020 0.46 [0.04; 5.75]
NCT04542694, 2020 13.03 [2.96; 57.24]
Pandit, 2021 2.33 [0.55; 9.83]
Ruzhentsova T, 2020 1.28 [0.92; 1.79]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
Tang, 2020 0.85 [0.58; 1.23]
Udwadia, 2020 1.37 [0.94; 1.98]
1.65 [1.15 ; 2.39 ] AVIFAVIR, 2020, Dabbous HM, 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, HC-nCoV (Shanghai), 2020, NCT04542694, 2020, Pandit, 2021, Ruzhentsova T, 2020, Shashi Bhushan, 2021, Tang, 2020, Udwadia, 2020 11 59% 1,189 moderate low viral clearance (time to event analysis only)detailed results Ruzhentsova T, 2020 1.28 [0.92; 1.79]
Tang, 2020 0.85 [0.58; 1.23]
Udwadia, 2020 1.37 [0.94; 1.98]
1.15 [0.86 ; 1.53 ] Ruzhentsova T, 2020, Tang, 2020, Udwadia, 2020 3 47% 468 moderate not evaluable viral clearance by day 14detailed results AVIFAVIR, 2020 3.08 [0.62; 15.39]
Bukhari, 2021 0.91 [0.02; 46.94]
ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76]
ELACOI (Standard of care), 2020 2.80 [0.31; 25.53]
Li T, 2020 1.00 [0.03; 34.67]
Pandit, 2021 10.23 [1.12; 93.35]
Ruzhentsova T, 2020 0.99 [0.93; 1.06]
Shashi Bhushan, 2021 0.00 [0.00; 0.01]
0.81 [0.11 ; 6.01 ] AVIFAVIR, 2020, Bukhari, 2021, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Li T, 2020, Pandit, 2021, Ruzhentsova T, 2020, Shashi Bhushan, 2021 8 94% 1,742 moderate not evaluable viral clearance by day 7detailed results AVIFAVIR, 2020 3.89 [1.23; 12.29]
Bukhari, 2021 11.56 [3.53; 37.91]
Dabbous HM, 2020 1.33 [0.60; 2.93]
ELACOI (lopinavir/ritonavir), 2020 0.30 [0.05; 1.91]
ELACOI (Standard of care), 2020 0.67 [0.10; 4.58]
Pandit, 2021 2.33 [0.55; 9.83]
PLACID, 2020 1.20 [1.00; 1.44]
Ruzhentsova T, 2020 1.05 [0.92; 1.20]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
1.62 [1.13 ; 2.31 ] AVIFAVIR, 2020, Bukhari, 2021, Dabbous HM, 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Pandit, 2021, PLACID, 2020, Ruzhentsova T, 2020, Shashi Bhushan, 2021 9 74% 1,087 moderate not evaluable ICU admissiondetailed results COL-COVID (Pascual-Figal), 2021 0.47 [0.08; 2.69]
FACCT Trial, 2021 1.42 [0.79; 2.55]
Khamis, 2020 1.03 [0.35; 3.03]
RAPID (Sholzberg), 2021 0.79 [0.48; 1.30]
0.98 [0.69 ; 1.39 ] COL-COVID (Pascual-Figal), 2021, FACCT Trial, 2021, Khamis, 2020, RAPID (Sholzberg), 2021 4 0% 911 moderate not evaluable recoverydetailed results GS-US-540-5774, 10 days, 2020 1.11 [0.90; 1.37]
GS-US-540-5774, 5 days, 2020 1.18 [0.96; 1.45]
1.15 [0.99 ; 1.33 ] GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 2 0% 796 moderate not evaluable serious adverse eventsdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.87 [0.36; 9.75]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.02 [0.20; 5.10]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
GS-US-540-5774, 10 days, 2020 0.55 [0.25; 1.23]
GS-US-540-5774, 5 days, 2020 0.50 [0.22; 1.14]
Krolewiecki, 2020 1.00 [0.03; 31.59]
NCT04523831 (Mahmud), 2020 3.97 [0.18; 88.58]
NCT04542694, 2020 6.15 [0.30; 124.49]
Pandit, 2021 0.95 [0.02; 50.33]
Ruzhentsova T, 2020 2.06 [0.09; 46.40]
Udwadia, 2020 1.03 [0.02; 52.48]
0.72 [0.45 ; 1.16 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COL-COVID (Pascual-Figal), 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Krolewiecki, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Pandit, 2021, Ruzhentsova T, 2020, Udwadia, 2020 11 0% 2,699 moderate critical acute kidney injury detailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.18 [0.44; 3.18]
1.18 [0.44 ; 3.18 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 345 NA not evaluable adverse eventsdetailed results ChiCTR2000030054-HCQ (Chen), 2020 5.00 [0.85; 29.57]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 2.22 [1.43; 3.44]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.88 [0.29; 2.65]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.21 [0.82; 1.78]
COL-COVID (Pascual-Figal), 2021 1.72 [0.73; 4.08]
GS-US-540-5774, 10 days, 2020 1.63 [1.09; 2.42]
GS-US-540-5774, 5 days, 2020 1.21 [0.82; 1.80]
HC-nCoV (Shanghai), 2020 1.45 [0.26; 8.01]
Krolewiecki, 2020 1.53 [0.42; 5.58]
NCT04523831 (Mahmud), 2020 18.57 [1.07; 322.77]
NCT04542694, 2020 1.00 [0.54; 1.85]
Pandit, 2021 1.68 [0.47; 5.97]
Ruzhentsova T, 2020 1.90 [0.96; 3.80]
Udwadia, 2020 6.36 [2.43; 16.65]
1.64 [1.27 ; 2.12 ] ChiCTR2000030054-HCQ (Chen), 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COL-COVID (Pascual-Figal), 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, HC-nCoV (Shanghai), 2020, Krolewiecki, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Pandit, 2021, Ruzhentsova T, 2020, Udwadia, 2020 14 41% 3,091 moderate low arrhythmiadetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 2.24 [0.23; 21.69]
2.24 [0.23 ; 21.69 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 416 NA not evaluable elevated liver enzymesdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 3.48 [1.40; 8.64]
3.48 [1.40 ; 8.64 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 416 NA not evaluable long QTdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 9.79 [1.27; 75.50]
9.79 [1.27 ; 75.50 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 174 NA not evaluable renal impairmentdetailed results COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.35 [0.47; 3.86]
1.35 [0.47 ; 3.86 ] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1 0% 331 NA not evaluable Thromboembolic eventsdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.89 [0.31; 2.55]
0.89 [0.31 ; 2.55 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 345 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-05 05:44 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 90
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290
